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Background: There is great interest in the design of small molecules that selectively target minor grooves of
duplex DNA for controlling specific gene expression implicated in a disease. The design of chiral small molecules
for rational drug design has attracted increasing attention due to the chirality of DNA. Yet, there is limited research
on the chirality effect of minor groove binders on DNA interaction, especially at the protein expression level. This
paper is an attempt to illustrate that DNA binding affinity might not provide a full picture on the biological
activities. Drug interacting at the genomic level can be translated to the proteomic level. Here we have illustrated
that although the chiral bispyrrole-pyrrolidine-oligoamides, PySSPy and PyRSPy, showed low binding affinity to DNA,
their influence at the proteomic level is significant. More importantly, the chirality also plays a role. Two-dimensional
proteomic profile to identify the differentially expressed protein in Escherichia coli DH5α (E coli DH5α) were
investigated.
Results: E coli DH5α incubated with the chiral PySSPy and PyRSPy, diastereomeric at the pyrrolidine ring, showed
differential expression of eighteen proteins as observed through two dimensional proteomic profiling. These
eighteen proteins identified by MALDI_TOF/TOF MS include antioxidant defense, DNA protection, protein
synthesis, chaperone, and stress response proteins. No statistically significant toxicity was observed at the tested
drug concentrations as measured via MTT assay.
Conclusion: The current results showed that the chiral PySSPy and PyRSPy impact on the proteomic profiling of
E coli DH5α, implicating the importance of drug chirality on biological activities at the molecular level.
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Genomics has dramatically altered the way of drug dis-
covery, and as such, small molecules with the ability to
sequence-selectively recognize and discriminate between
DNA have become increasingly important for the con-
trol of specific processes involved in gene expression im-
plicated in diseases [1-5]. The minor grooves of DNA
have been shown to play important roles in the regula-
tion of gene expression and are normally unoccupied
[6], hence they are considered a susceptible site of attack* Correspondence: tinayang101@gmail.com; jyjeng@hotmail.com
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reproduction in any medium, provided the orby small molecules less than 1000 kDa [7]. Consequently
much interest has been concentrated in the design of
small molecules that selectively target minor grooves of
duplex DNA in order to control specific gene expression
implicated in a disease [1]. There is limited research
investigating the chirality effect of minor groove bin-
ders on DNA interaction. The dimerization of two
N-methylpyrrole oligopeptides through the chiral linker
methanodiazocin scaffold has shown that the (4R,9R)-
form is better suited for interaction with calf thymus
DNA than the (4S,9S)-form [8]. In addition, Herman
et al. (1998) has shown that the enantiomer derived
from two distamycin A-derived polyamides linked by
either (R)-2,4-diaminobutyric acid showed enhanced
binding affinity towards DNA when compared to thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ratory has recently designed and synthesized two dista-
mycin A-derived diastereoisomers, depicted as PySSPy
and PyRSPy [10]. These two diastereoisomers have their
middle pyrrole group replaced with a pyrrolidine group
and the terminal amide group removed (Figure 1).
Genome research has led to medical advances against
diseases [11,12]. However, human complexity cannot be
entirely explained by its genomics, but by the way their
gene products interact. To further complicate the mat-
ter, genome is a static process while proteome is a dy-
namic process. In other words, one gene can encode for
a number of proteins. While most drugs target proteins,
disease profiling is at present dominated by DNA
microarrays [13-15]. As such, there may not be a good
correlation between gene expression and protein ex-
pression in most disease processes, and treatments can
be manifested at the protein level. Thus, it is believed
that gene-based expression analysis alone is inadequate
for drug discovery.
In the past, protein expression has been analyzed
through mRNA studies. However, it was later shown
that mRNA content does not correlate with protein con-
tent as mRNA is not always translated into protein
[16-19]. On the other hand, proteomics is a systematic
analysis that measures protein expression directly and
not via gene expression, yet serving as a complementary
approach to genomics. 2D gel electrophoresis is still the
most useful way to separate proteins in complex samples
in proteomics profiling and allows simultaneous analyses
of vast amount of protein data, making it suitable for
comparative analysis of a reference cell protein profile
with a profile after drug treatment in the search of new
drug or drug target. At present there are minimal re-
searches on the consequences of DNA minor groove
binding agents on the proteomic profile in cells.Figure 1 Chemical structures of distamycin A, PySSPy, PyRSPy and 3A
(3A), a distamycin-A derived achiral compound retaining the middle pyrrolEscherichia coli (E. coli) are one of the best-characterized
prokaryotes. Since the completion of the E. coli genome-
sequencing project [20], this organism has been studied on
the genome wide scale in terms of its transcriptome, prote-
ome, interactome, metabolome, and physiome [21-25].
The uses of proteomics technologies on E coli have gener-
ated unprecedentedly large amounts of proteome data for
E coli [25-27]. This extensive E coli proteome database has
therefore made E coli an ideal model organism for a large-
scale comparison of protein expression levels under par-
ticular chemical and physical stresses [26]. Our initiative is
to examine whether proteomics is a more realistic end
point for drug action, and at the same time the chirality ef-
fects on protein expression. To achieve this goal, we have
synthesized chiral compounds PySSPy and PyRSPy and
performed the proteomic profiling analyses on an E. Coli
DH5α strain by performing 2D gel electrophoresis coupled
with mass spectrophotometry to determine the expres-
sional changes on different proteins. This method allows
us to carry out a simultaneous search on a vast number of
proteins that may have expressional changes. We have also
examined the protein expressional changes of E. Coli
DH5α in response to tripyrrole-oligoamide (3A). This
compound is also a distamycin A-derived compound,
which retains the middle pyrrole group that is achiral. The
proteomic profiling of the achiral 3A is examined to con-
firm the influence of chirality. Although there are numer-
ous differentially expressed proteins, in this work we have
identified the most significant eighteen proteins that have
either been up- or down-regulated, and the chirality of the
compound was found to play an important role.
Results
Susceptibility of E coli DH5α to bispyrrole-pyrrolidines
To examine the susceptibility of Escherichia coli DH5α
(E coli DH5α) towards PySSPy, E coli DH5α treated with. (A) Distamycin A. (B) PySSPy (C) PyRSPy (D) Tripyrrole-oligoamide
e group.
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cell growth via OD600 analyses (Additional file 1). The
growth curve of the non-treated cells exhibited a 6-hour
lag phase, followed by a 6-hour exponential phase
and subsequently a stationery phase. At 9-hr incuba-
tion, E coli DH5α treated with 100, 150, 200 and
300 μM PySSPy showed approximately 8 (p < 0.01),
10 (p < 0.001), 12 (p < 0.001) and 20% (p < 0.001)
decreases in cell density, respectively. However, the
growth curves of the PySSPy treated cells eventually
reached the same plateaus as that of the control cells. The
results indicate the non-toxic nature of PySSPy on E coli
DH5α. A concentration of 300 μM was subsequently
chosen for the rest of the study to maximize the possible
effects of PySSPy on E coli DH5α proteome.
The cytotoxicity of PySSPy, PyRSPy and 3A was sub-
sequently compared (Figure 2). Exposure of E coli
DH5α to either 300 μM PySSPy or PyRSPy resulted in
approximately 20% decreases in cell viability at 9-hr
time period (p < 0.001), after which the cell growth
curves became comparable to that of the control (p >
0.05). Exposure of E coli DH5α to 300 μM 3A resulted
in no statistically significant decreases in cell density
over time. Overall, these results suggest that PySSPy and
PyRSPy have limited cytotoxicity effects on E coli DH5α
even at a high concentration of 300 μM.Figure 2 E. coli DH5α growth after treatment with PySSPy,
PyRSPy and 3A. E. coli DH5α in LB broth were treated with 0
(square), or 300 μM PySSPy (triangle), PyRSPy (circle), and 3A
(diamond) at 37°C for 15 hours. Cell density was determined at time
intervals through OD600 measurement. Each data point was
subtracted from blank controls. Each data point was the mean result
of triplicate values. Standard deviations were calculated for each
data point and presented as error bars.Proteomic analyses
The lack of cytotoxicity observed in PySSPy- and PyRSPy-
and 3A-treated E. coli DH5α allows the further study of
their influence at the molecular level associated with the
global protein expression. Differential protein expression
in E. coli DH5α cells following exposure to 300 μM
PySSPy, PyRSPy and 3A for 9 hours were examined using
a comparative proteomic analysis. Protein spots resulted
from the PySSPy-, PyRSPy- and 3A-treated 2-DE gels
were compared with the corresponding protein spots from
the control gel. The proteomic profiles of total proteins
from the control and treated E. coli DH5α from three in-
dependent experiments were shown in Additional files 2,
3, 4 to 5.
The representative proteomic profile of total proteins
from the control E. coli DH5α showed that proteins were
widely distributed across the pI range (4-7) between the
molecular weight 16 and 143 kDa (Figure 3). After com-
parison with the control, some protein spots from the
PySSPy-, PyRSPy- and 3A-treated gels with significant ex-
pressional change were excised from the gels (Figure 4) and
identified by MALDI-TOF mass spectrometry using pep-
tide mass fingerprint searches (Table 1). Eighteen protein
spots in total were successfully identified with significant
scores and high sequence coverage. The abundance of the
remaining protein spots were either too low to be detectedFigure 3 Two-dimensional proteomic map of soluble proteins
in E. coli DH5α. E. coli DH5α were treated in the absence of any
distamycin A derivatives at 37°C for 10 hours, followed by cell
protein solubilization via high intensity ultrasonication in rehydration
buffer. The soluble protein (240 μg) was separated on an
immobilized pH gradient gel strip (pH 4-7) and 12% SDS-PAGE gel.
Proteins were visualized by staining with commercial SimplyBlue
SafeStain. The numbers correspond to the numbers listed in
Figure 4 and Table 1.
Figure 4 The expression of the proteins identified in E. coli DH5α after treatment with distamycin-A derivatives. E. coli DH5α were
treated in the absence (control) or presence of 300 μM PySSPy, 300 μM PyRSPy or 300 μM 3A at 37°C for 10 hours, followed by cell protein
solubilization and protein separation using an immobilized pH gradient gel strip (pH 4-7) and 12% SDS-PAGE gel. The gels were visualized using
commercial SimplyBlue SafeStain. The resulting proteomic maps were shown in enlarged sections for comparison with the non-treated control.
The numbers represent the proteins that show either up- or down-regulation in E. coli DH5α in response to PySSPy, PyRSPy and 3A, compared
with the non-treated control. These numbers correspond to the numbers listed in Figure 3 and Table 1.
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suggests that PySSPy. PyRSPy and 3A at a non-cytotoxic
concentration can still induce alteration in protein
expression.
The 18 proteins in E coli DH5α identified that showed
differential expression in response to either PySSPy or
PyRSPy or both are listed in Table 1. Both PySSPy
and PyRSPy induced significant down-regulation of
serine hydroxymethyltransferase, glycerol kinase, succin-
ate dehydrogenase iron-sulfur subunit, NADP-dependent
malic enzyme and DNA protection during starvation
protein. Malate dehydrogenase, 2-dehydro-3-deoxy-D-
gluconate 5 dehydrogenase and 60 kDa chaperonin 1 were
significantly up-regulated by both PySSPy and PyRSPy.
Interestingly, selective proteins were differentially
expressed in response to either PySSPy or PyRSPy alone.
PySSPy alone significantly down-regulated phosphoenol-
pyruvate carboxykinase, aminomethyltransferase and
superoxide dismutase [Fe], and up-regulated ATP syn-
thase subunit beta and elongation factor Tu 1. PyRSPy
alone significantly up-regulated tryptophanase, bifunc-
tional purine biosynthesis protein purH, chaperone pro-
tein dnaK, alkyl hydroperoxide reductase subunit C and
KHG/KDPG aldolase. In addition, the control 3A alone
did not induce differential protein expression. The results
suggest these two diastereoisomers differing only in theirchiral center show protein selectivity, whereas the chiral
3A is less selective in protein expression regulation.
The proteins identified can be classified into several
groups using the UniProtKB database and the KEGG
database based on their molecular functions, including
transferases, oxidoreductases, lyases, hydrolases, elon-
gation factor, and chaperone. These proteins are in-
volved in metabolism (serine hydroxymethyltransferase,
NADP-dependent malic enzyme, glycerol kinase, phos-
phoenolpyruvate carboxykinase, aminomethyltransferase,
2-dehydro-3 deoxy-D-gluconate 5-dehydrogenase, succin-
ate dehydrogenase iron-sulfur subunit, ATP synthase sub-
unit beta, bifunctional purine biosynthesis protein purH,
tryptophanase, KHG/KDPG aldolase and malate dehydro-
genase), antioxidant defense (superoxide dismutase [Fe],
DNA protection during starvation protein and alkyl
hydroperoxide reductase subunit C), protein synthesis
(elongation factor Tu 1), DNA replication (chaperone
protein dnaK) and stress response (60 kDa chaperonin
1), rather than taking part in a wide variety of biological
processes.
Discussion
Selective and cytostatic anticancer agents may not express
their biological activities through cell death or tumor
Table 1 Identification of differentially expressed proteins of E coli DH5α treated with PySSPy, PyRSPy and 3A















6.03/94 9 (22) 29 -25 ± 04 -2.1 ± 0.2 -1.4 ± 0.1








5.24/27 8 (18) 40 +1.7 ± 0.1 +2.0 ± 0.2 +1.9 ± 0.2
5 IvEH_ECO24 Malate dehydrogenase 5.61/32 11 (22) 49 +2.3 ± 0.2 +3.1 ± 0.05 +1.9 ± 0.06












5.46/60 14 (27) 35 -24 ± 0.2 NS NS
10 GCST_EC024 Aminomethyltransferase 5.36/40 9 (17) 35 -2.1 ± 0.3 NS NS
11 SODF_ECO57 superoxide dismutase [Fe] 5.58/53 15 (16) 37 NS +1.9 ± 0.009 NS
12 ATPB_EC024 ATP synthase subunit beta 4.9150 16 (50) 50 +3.0±0.2 NS +2.6 ± 0.2
13 EFTIJ1_EC024 Elongation factor Tu 1 53143 17 (44) 53 +3.3 ± 0.2 NS +3.1 ± 0.1




5.53/58 11 (14) 31
NS
+1.3 ± 0.2 +1.6 ± 0.06




5.0/21 6 (11) 43 NS +2.6 ± 0.3 +2.5 ± 0.4
18 ALKH_ECO57 KHG/KDPG aldolase 5.57/22 7 (20) 46 NS +1.8 ± 0.2 +2.1 ± 0.3
a “-” indicates down-regulation and “+” indicates up-regulation. The numerical values indicate the relative intensities of protein spots of interest in comparison
with the corresponding control proteins, and they are presented as mean ± standard deviations of at least 2 independent proteomic gels. “NS” indicates the
intensity changes are statistically non-significant in comparison to the corresponding control proteins.
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of protein to effect survival. The synthesized PySSPy,
PyRSPy and 3A showed weak binding to calf thymus
DNA [10] and low cytotoxicity (Figure 2). Even so, the
current study using 2- dimensional gel electrophoresis
coupled with mass spectrophotometry [28-31] has allow
us to identified 18 responsive proteins involved in diffe-
rent biological processes to be up- or down regulated by
these compounds (Figure 4 and Table 1). This illustrate
that proteomics may be a more important to fully
expressed the interaction of drugs at the cellular level.
Here, PySSPy and PyRSPy were shown to selectively affect
several proteins, and these results are promising.
The achiral compound 3A was found to be less selective
in influencing particular protein expression. Its impacts
on protein expression seemed to be more random as com-
pared to those of PySSPy and PyRSPy, implying the
importance of chirality in regulating selective protein ex-
pression. The 18 proteins with altered expression level inPySSPy- and PyRSPy-treated E coli DH5α can be cate-
gorized into a broad range of different functional clas-
ses, including metabolism, cellular defenses, DNA
replication, stress responses, and protein synthesis. The
wide range of different proteins involved suggested that
PySSPy and PyRSPy can induce profound biological re-
sponses in E coli DH5α.
Among the 18 proteins, PySSPy alone has shown to
down-regulation of 3 proteins and up regulation of 2
proteins, whereas PyRSPy alone up-regulated 5 proteins
(Table 1). This result suggests that PySSPy and PyRSPy
that differ only in configuration of one stereogenic cen-
ter can alter the expression of selective genes. This indi-
cates that these chiral compounds may exert differential
cellular effects. The present preliminary data illustrate
the importance of coupling proteomics studies with gen-
omic studies to obtain a clearer picture for the biological
activities of drugs. Of interest is the down-regulation of
phosphoenolpyruvate carboxykinase by PySSPy because
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the conversion of oxaloacetate to phosphoenolpyruvate
in humans. This metabolite can be converted to pyru-
vate in the glycolytic pathway or to glucose in the gluco-
neogenesis pathway.
Another noteworthy finding in the present study is the
up-regulation of chaperone protein dnaK (DnaK) after
PyRSPy treatment (Table 1). DnaK is a chaperone pro-
tein in bacteria belonging to the heat shock 70 kDa
(Hsp70) chaperone protein family. When bound to ADP,
DnaK binds to exposed hydrophobic residues of un-
folded or partially mis-folded proteins, stabilizing them
and giving them time to fold correctly [32]. DnaK is also
involved in stabilizing precursor proteins, assisting the
translocation of newly synthesized proteins, and
protecting cells against cellular stress [33]. For many
years Hsp70 in humans has been implied to play a
neuroprotective role in some neuron degenerative dis-
eases [34]. Hsp70 levels have been shown to decrease
along with disease progression in the Huntington’s dis-
eased mouse brain, implicating its role in preventing the
pathogenesis of the disease [35]. Furthermore, Hsp70
overexpression has been shown to reduce α-Syn protein
aggregate formation and toxicity in a mouse model of
Parkinson’s disease [36], and has caused mice to be more
resistant to neurodegeneration following brain ischemia
[37]. Hence, it is important to examine the effects of
PySSPy and PyRSPy on the expressional changes of
phosphoenol-pyruvate carboxykinase and DnaK, respect-
ively, and the toxicity effects of these two compounds
using a human cell line system to address their possible
clinical importance.
Conclusion
We have shown for the first time through a proteomic
approach that distamycin A-derived chiral compounds
selectively regulate the expression of proteins at the mo-
lecular level. These compounds’ non-cytotoxic nature
are implicative of their potential in altering a particular
cellular pathway without inducing cellular toxicity in
host cells, hence offering the prospect of new drug de-
velopment. The future studies are aimed at investigating
whether these compounds exerted the same effects on
human cells as on bacterial cells. Furthermore, the sig-
nificance of these compounds in altering a particular cel-




Tris-HCl, tris-base, phosphate buffer saline (PBS), 3-[(3-
cholamido-propyl)di-methylammonio]-1-propanesulfonate
(CHAPS), iodoacetamide and acrylamide (40%) were
purchased from Amresco (OH, USA). Urea, glycerol,ammonium persulfate, and ammonium bicarbonate were
purchased from Showa Chemicals Inc. Bradford protein
assay kit and dithiothreitol (DTT) were obtained from
GMbiolab Co. Ltd. Formic acid, trifluoroacetic acid and
N,N,N',N'-Tetramethyl-1-,2-diamino-methane were pur-
chased from Sigma-Aldrich, Co. Acetonitrile, thiourea and
sodium dodecyl sulfate (SDS) were obtained from Merck.
Pre stained protein marker and SimplyBlue SafeStain were
purchased from Invitrogen (NY, USA), and α-cyano-4-hy-
droxy-cinnamic acid from Tokyo Kasei Kogyo Co., Ltd
(TCI). Immobilline Dry Strips (pH 4-7, 7 cm, linear gradi-
ent) and immobilized pH gradient (IPG) buffer (pH 4-7)
were purchased from GE healthcare.
Cell culture and treatment
A single colony of Escherichia coli DH5α (E coli DH5α)
removed from agar containing Lysogeny broth (USB
Products) was suspended in each of the 100 ml of lysog-
eny broth media and grown for 24 hours by shaking at
160 rpm at 30°C. Subsequently, the cells were trans-
ferred into fresh lysogeny broth media (0.03% (v/v)) for
a further 12 hours in the absence or presence of PySSPy,
PyRSPy and 3A.
Cell growth determination
E coli DH5α were assessed for their cell growth by meas-
uring their turbidity at 600 nm (OD600) using an ELISA
plate reader (Thermo Multiskan Ascent). Triplicate sam-
ples from each treatment were obtained for the deter-
mination of mean values and standard deviations.
Sample preparation for isoelectric focusing (IEF)
Cells collected at the end of the incubation period were
washed with phosphate buffer saline (PBS) and the final
time with nanopure water at 9000 rpm at 15°C. The cell
pellet was subsequently lysed by re-suspension in 0.5 ml
rehydration buffer (7 M urea, 2 M thiourea and 4% (w/v)
CHAPS) and ultrasonication (Elmasonic E70H) for a total
of 1 minute on ice. The supernatant, after centrifugation
of the lysate at 12 000 rpm at 4°C, was measured for pro-
tein content using the Bradford protein determination kit
and stored at -20°C.
Isoelectric focusing and second dimension SDS-PAGE gel
electrophoresis
Protein samples (240 μg) were prepared by precipitation
of the protein supernatant in 70% acetonitrile on ice for
20 minutes. The protein pellet was then dissolved in
120 μl of rehydration buffer (7 M urea, 2 M thiourea
and 4% (w/v) CHAPS), 50 mM dithiothreitol (DTT) and
2% IPG buffer (pH 4-7).
After rehydrating the 7-cm IPG strips (pH 4–7) with
the samples for 15 hours, isoelectric focusing (IEF) was
conducted on these IPG strips by using a Protean IEF
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voltage-hours for optimum focusing. After focusing, a
conditioning step was conducted by treating the strips
in equilibration buffer I (6 M urea, 0.375 M Tris-HCl,
pH 8.8, 2% SDS (w/v), 20% glycerol (w/v) and 130 mM
DTT) for 30 minutes and equilibration buffer II (6 M urea,
0.375 M Tris-HCl, pH 8.8, 2% SDS (w/v), 20% gly-
cerol (w/v) and 135 mM iodoacetamide) for another
30 minutes.
The second dimension (2D) SDS-PAGE gel was run by
using 12% resolving gels composed of 12% acrylamide,
0.375 M Tris-HCl, pH8.8, 0.1% SDS, 0.1% ammonium
persulfate, 0.08% (v/v) N,N,N',N'-Tetramethyl-1-,2-
diamino-methane, and 0.5% stacking gel (0.5% (w/v)
agarose and 0.002% (w/v) bromophenol blue). The gels
were stained with SimplyBlue SafeStain and directly
scanned using a Microter 4100 scanner. The corre-
sponding protein spots of interest from each different
gel image were analyzed for their intensities using the
ImageJ software (version 1.46), available on http://
rsbweb.nih.gov/ij/download.html. The protein intensities
were normalized by dividing the intensities of the pro-
tein spots of interest by the intensity of a chosen protein
spot in the same gel, whose intensity is considered not
significantly changed across all the control and treated
gels. The relative intensities of protein spots of interest
were calculated by dividing the intensities of protein
spots of interest by the intensities of the corresponding
protein spots in the controls. The mean fold changes
and the standard deviations in Table 1 were obtained
from triplicate gel samples.
In-gel digestion, MALDI-MS analyses, and protein
identification
The procedure for In-gel digestion was described by the
Biological Mass Spectrometry Laboratory, the Ontario
Wide Protein Identification Facility. Please refer to the
website http://www.biochem.uwo.ca/wits/bmsl/index.html.
Briefly, protein spots were excised and incubated with 40
μl of 50% acetonitrile in nanopure water for 15 minutes,
followed by incubating the gel pieces with 100 mM
ammonium bicarbonate and acetonitrile in 1:1 ratio for 15
minutes. The gel pieces were subsequently dried in a
speedvac and incubated with 40 μl of 50 mM DTT/100
mM ammonium bicarbonate at 56°C for 45 minutes. The
gel pieces, after removal of the supernatant, were incubated
with 40 μl of 200 mM iodoacetamide/100 mM ammonium
bicarbonate at room temperature for 45 min in the dark.
After discarding the supernatant at the end of the incuba-
tion, the gel pieces were treated with 40 μl of 5 ng/μl se-
quencing grade modified trypsin (Promega, Madison, WI)
in 25 mM ammonium bicarbonate and the mixtures were
incubated overnight at 37°C. The supernatants from the
trypsin-digested mixtures were collected in separate tubes,and peptides were extracted twice by treating the gel pieces
with 30 μl of acetonitrile/5% formic acid in 1:1 ratio. The
extracts were completely dried using a Speed Vac.
The dried peptides were dissolved in 5 μl of 0.1% formic
acid. One μl of peptide samples were mixed with 1 μl of
matrix solution (30 mg/ml α-cyano-4- hydroxycinnamic in
70% acetonitrile/0.1% trifluoroacetic acid) onto a matrix-
assisted laser desorption/ionization (MALDI) plate, and
allowed to air-dry. Spectra were acquired using Bruker
Daltonics Autoflex III/Autoflex III TOF/TOF (serial num-
ber 238.120.00103). Peptide calibration for a mass range of
m/z 500 to m/z 2500 was performed using α-cyano-4-
hydroxycinnamic acid (α-CHCA), angiotensin I, and adre-
nocorticotropic hormone (ACTH). The peak lists obtained
were searched using Mascot search engine, and compared
against non-redundant NCBI protein database. The fol-
lowing parameters were used: maximum allowed missed
cleavages by trypsin was 1; fixed amino acid modification
as carbamidomethyl; Escherichia coli was chosen for the
taxonomy; the peptide tolerance for spectra obtained from
MALDI was ± 0.5Da. Only protein samples with MOWSE
scores above the significant threshold level (p ≤ 0.05) as
determined by MASCOT were listed in Table 1. The pro-
teins identified were classified into different molecular
functions, the elemental activities of a gene product at
molecular level, using the Uni Protein Knowledgebase
(UniProtKB) database available on http://www.uniprot.org/.
Statistical analysis
Data was plotted and statistically analyzed using the Prism
software program (GraphPad Software, USA). Significance
was confirmed by a one-way analysis of variance [8] and
Tukey’s multiple comparison test. Significance levels are
indicated in the following manner: * p ≤ 0.05; ** p ≤ 0.01;
*** p≤ 0.001. The means and standard deviations shown
within each experiment were calculated from triplicate
samples.
Additional files
Additional file 1: E. coli DH5α cell growth after treatment with the
distamycin A derivative PySSPy. E. coli DH5α in LB broth were treated
with 0 (dark square), 50 (inverted white triangle), 100 (white triangle), 150
(white circle), 200 (white diamond), 300 (white square) μM PySSPy at 37°C
for 15 hours. Cell density was determined at time intervals through OD 600
measurement. Each data point was subtracted from blank controls. Each
data point was the mean result of triplicate values. Standard deviations
were calculated for each data point and presented as error bars.
Additional file 2: The proteomic gel images of E. coil DH5α control.
E. coil DH5α were treated in the absence of 300 μM PySSPy. 300 μM
PyRSPy or 300 μM 3A at 37°C for 10 hours, followed by 2D gel
electrophoresis. The gels were visualized using commercial SimplyBlue
SafeStain. The gels images A), B) and C) were obtained from three
independent experiments.
Additional file 3: The proteomic gel images of E. coil DH5α treated
with PySSPy. E coli DH5α were treated with 300 μM PySSPy at 37°C for
10 hours, followed by 2D gel electrophoresis. The gels were visualized
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were obtained from three independent experiments.
Additional file 4: The proteomic gel images of E. coil DH5α treated
with PyRSPy. E. coli DH5α were treated with 300 μM PyRSPy at 37°C for
10 hours, followed by 2D gel electrophoresis. The gels were visualized
using commercial SimplyBlue SafeStain. The gels images A), B) and C)
were obtained from three independent experiments.
Additional file 5: The proteomic gel images of E. coil D115u treated
with 3A. E. coil DH5α were treated with 300 μM 3A at 37°C for 10 hours,
followed by 2D gel electrophoresis. The gels were visualized using
commercial SimplyBlue SafeStain. The gels images A), B) and C) were
obtained from three independent experiments.
Abbreviations
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